Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label study of carfilzomib + dexamethasone versus bortezomib + dexamethasone in relapsed multiple myeloma
CTR20190717Phase 3Active
- Sponsor
- Amgen
- Start
- Nov 2019
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of carfilzomib in multiple myeloma (MM), sponsored by Amgen. Started Nov 2019; status: active.
02
Drugs
carfilzomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on CTR20190717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190717.